Acme United

Capital deployment has emphasized tuck-in acquisitions at modest sizes, capacity additions and automation, alongside a rising but modest dividend (0.16 dollars per quarter declared March 12, 2026). Buybacks have been minimal since 2019 authorization and we prefer this focus on reinvestment while leverage is elevated post-My Medic.

My Medic cost 18.6 million (14.4 million cash plus holdback and earnout) and contributed 3.4 million revenue in Q1 2026; Elite First Aid and a German cutting line broaden product offerings and geographies. We view the M&A track record as prudent, with synergy capture and working-capital discipline as the key near-term proof points.